DHF
MCID: DNG002
MIFTS: 58

Dengue Hemorrhagic Fever (DHF)

Categories: Blood diseases, Infectious diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Dengue Hemorrhagic Fever

MalaCards integrated aliases for Dengue Hemorrhagic Fever:

Name: Dengue Hemorrhagic Fever 11 53 14 16
Severe Dengue 43 71 33
Dengue Haemorrhagic Fever 11 31
Severe Dengue Haemorrhagic Fever 33
Dengue Shock Syndrome 33
Severe Dengue Fever 33
Dhf 11

Classifications:



External Ids:

Disease Ontology 11 DOID:12206
MeSH 43 D019595
NCIt 49 C34683
SNOMED-CT 68 20927009
ICD10 31 A91
ICD11 33 56575149
UMLS 71 C0019100

Summaries for Dengue Hemorrhagic Fever

Disease Ontology: 11 A dengue disease that occurs when a person experiences a second infection with a heterologous Dengue virus serotype, which is transmitted by Aedes mosquito bite. The infection has symptom hemorrhagic lesions of the skin, has symptom thrombocytopenia, has symptom reduction in the fluid part of the blood, and has symptom high fever.

MalaCards based summary: Dengue Hemorrhagic Fever, also known as severe dengue, is related to dengue disease and panophthalmitis, and has symptoms including hemorrhagic lesions of the skin, thrombocytopenia and reduction in the fluid part of the blood. An important gene associated with Dengue Hemorrhagic Fever is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and MIF Mediated Glucocorticoid Regulation. The drugs Benzocaine and Tannic acid have been mentioned in the context of this disorder. Affiliated tissues include skin, myeloid and endothelial, and related phenotypes are no effect and no effect

Related Diseases for Dengue Hemorrhagic Fever

Diseases related to Dengue Hemorrhagic Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 926)
# Related Disease Score Top Affiliating Genes
1 dengue disease 31.5 TNF SENP8 PTPN11 IVNS1ABP IL6 IL10
2 panophthalmitis 31.1 SENP8 CD4
3 disseminated intravascular coagulation 31.1 TNF IL6 IL10
4 pancreatitis 30.9 TNF IL6 IL10 CXCL8
5 pulmonary edema 30.9 TNF IL10 CXCL8
6 acalculous cholecystitis 30.9 SENP8 CD4
7 typhoid fever 30.9 TNF LTA IL6 CCR6
8 acute pancreatitis 30.8 TNF IL6 IL10 CXCL8
9 chikungunya 30.7 TNF IL6 CD209
10 hantavirus pulmonary syndrome 30.7 LTA ERVW-1 CD8A
11 peritonitis 30.7 TNF IL6 IL10 CXCL8
12 glomerulonephritis 30.7 TNF IL6 IL10 CD40LG
13 myositis 30.6 TNF IL6 IFNA1 HLA-B
14 filariasis 30.6 TNF IL6 IL10
15 myocarditis 30.6 TNF IL6 IL10 IFNA1 CXCL8 CD40LG
16 thrombocytopenia 30.5 TNF PTPN11 IL6 IL10 IFNA1 HLA-B
17 dengue shock syndrome 30.5 TNF SENP8 IVNS1ABP IL6 IL10 IFT81
18 filarial elephantiasis 30.5 TNF IL10 CD8A CD4
19 schistosomiasis 30.5 TNF IL10 CD40LG
20 appendicitis 30.5 TNF IL6 IL10 CXCL8
21 zika fever 30.5 IFNA1 ERVW-1 CD209
22 exanthem 30.5 TNF IL6 IL10 IFNA1 HLA-B CXCL8
23 haemophilus influenzae 30.5 TNF CXCL8
24 endophthalmitis 30.5 TNF IL6 CXCL8 CD4
25 acute disseminated encephalomyelitis 30.5 IL6 CD8A CD4 CCR6
26 adult respiratory distress syndrome 30.5 TNF LTA IL6 IL10 FCGR2A CXCL8
27 thrombocytopenic purpura, autoimmune 30.4 FCGR2A CD8A CD4 CCR6
28 toxic shock syndrome 30.4 TNF LTA IL6 IL10 CXCL8
29 toxoplasmosis 30.4 TNF IL6 IL10 CD40LG
30 heart disease 30.4 TNF PTPN11 LTA IL6 IL10 IFNA1
31 hemophagocytic lymphohistiocytosis 30.4 TNF IL6 IL10 CXCL8 CD8A CD4
32 orbital cellulitis 30.4 IL6 CD8A CD4
33 pericardial effusion 30.4 TNF IL6 CD4
34 pericarditis 30.4 TNF IL6 CXCL8
35 japanese encephalitis 30.4 SENP8 IVNS1ABP IFNA1 ERVW-1 CLEC4M CD8A
36 acute kidney tubular necrosis 30.4 TNF IL6 CCR6
37 epidemic typhus 30.4 IL10 CD8A CD4
38 inflammatory bowel disease 1 30.4 TNF IL6 IL10 CCR6
39 measles 30.4 IL6 IFNA1 CD40LG CD209
40 gingivitis 30.3 TNF IL6 IL10 CXCL8
41 vasculitis 30.3 TNF IL6 IL10 HLA-B CXCL8 CD40LG
42 alcoholic liver cirrhosis 30.3 TNF IL6 CXCL8
43 purpura 30.3 TNF IL6 IL10 FCGR2A CXCL8
44 aspergillosis 30.3 TNF IL6 IL10 CXCL8 CD209 CCR6
45 crimean-congo hemorrhagic fever 30.3 IL6 IL10 IFNA1 ERVW-1
46 hepatitis a 30.3 TNF IL10 IFNA1 CD4
47 rhinitis 30.3 TNF IL6 IL10 CXCL8
48 ileus 30.3 TNF IL6 IL10
49 alcoholic hepatitis 30.3 TNF IL6 IL10 CXCL8
50 invasive aspergillosis 30.3 TNF IL6 IL10 CD4 CD209 CCR6

Graphical network of the top 20 diseases related to Dengue Hemorrhagic Fever:



Diseases related to Dengue Hemorrhagic Fever

Symptoms & Phenotypes for Dengue Hemorrhagic Fever

Symptoms:

11
  • hemorrhagic lesions of the skin
  • thrombocytopenia
  • reduction in the fluid part of the blood
  • high fever

GenomeRNAi Phenotypes related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 CCR6 CD209 CD4 CD40LG CD8A CLEC4M
2 no effect GR00402-S-2 10.18 CCR6 CD209 CD4 CD40LG CLEC4M CLEC5A

MGI Mouse Phenotypes related to Dengue Hemorrhagic Fever:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.17 CD4 CD40LG CD8A FCGR2A HLA-B IFT81
2 cellular MP:0005384 10.15 CD209 CD4 CD40LG CD8A CLEC4M FCGR2A
3 immune system MP:0005387 10.13 CCR6 CD209 CD4 CD40LG CD8A CLEC4M
4 digestive/alimentary MP:0005381 10.06 CD209 CD4 CLEC4M FCGR2A HLA-B IL10
5 cardiovascular system MP:0005385 10.06 CCR6 CD40LG FCGR2A HLA-B IFT81 IL10
6 hematopoietic system MP:0005397 9.8 CCR6 CD209 CD4 CD40LG CD8A CLEC4M
7 respiratory system MP:0005388 9.76 FCGR2A IFNA1 IL10 IL6 IVNS1ABP LTA
8 mortality/aging MP:0010768 9.47 CD209 CD4 CD40LG CD8A CLEC4M FCGR2A

Drugs & Therapeutics for Dengue Hemorrhagic Fever

Drugs for Dengue Hemorrhagic Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 16)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
2
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
3
Montelukast Approved Phase 2, Phase 3 158966-92-8 5281040
4 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
5 Pharmaceutical Solutions Phase 3
6 Leukotriene Antagonists Phase 2, Phase 3
7 Hormones Phase 2, Phase 3
8 Hormone Antagonists Phase 2, Phase 3
9 Respiratory System Agents Phase 2, Phase 3
10 Anti-Asthmatic Agents Phase 2, Phase 3
11 Vaccines Phase 3
12 Immunologic Factors Phase 3
13
Ivermectin Approved, Investigational, Vet_approved Phase 2 70288-86-7 9812710 6427057
14 Anti-Infective Agents Phase 2
15 Antiparasitic Agents Phase 2
16 Hemostatics Phase 2

Interventional clinical trials:

(show all 43)
# Name Status NCT ID Phase Drugs
1 Albumin 5% as Resuscitation in Adult Dengue Fever Patients With Plasma Leakage Unknown status NCT04076254 Phase 3 Albumins;Fluid
2 The Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as a Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients Unknown status NCT00966628 Phase 3 Hypertonic sodium lactate;Ringer's lactate
3 Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril®) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru Completed NCT01436396 Phase 3
4 Lot-to-Lot Consistency and Bridging Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
5 Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Completed NCT01373281 Phase 3
6 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
7 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia Completed NCT02993757 Phase 3
8 Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Completed NCT01374516 Phase 3
9 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® in Healthy Female Subjects Aged 9 to 14 Years in Mexico Completed NCT02979535 Phase 3
10 Immunogenicity and Safety of a Booster Injection of DTaP-IPV//Hib (Pentaxim™) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in Mexico Completed NCT01411241 Phase 3
11 Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients: a Multicenter Randomized, Double-blind, Placebo Controlled, Superiority Trial Recruiting NCT04673422 Phase 2, Phase 3 Montelukast;Placebo
12 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Aged 9 to 60 Years in the Philippines Terminated NCT02992418 Phase 3
13 Efficacy and Safety of Dengue Vaccine in Healthy Children Aged 4 to 11 Years in Thailand Completed NCT00842530 Phase 2
14 Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years Previously Vaccinated Against Yellow Fever in Peru Completed NCT00788151 Phase 2
15 Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in South America Completed NCT01187433 Phase 2
16 Immunogenicity and Safety of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India. Completed NCT01550289 Phase 2
17 Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients Completed NCT03432442 Phase 2 Ivermectin
18 Safety and Immunogenicity of Bivalent and Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Flavivirus-Naïve Adults Aged 18 to 45 Years Completed NCT00740155 Phase 2
19 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Latin America Completed NCT02623725 Phase 2
20 Evaluation of the Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Administered With or Without Yellow Fever Vaccine in US Adults. Completed NCT01488890 Phase 2
21 Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Previously Immunised With an Investigational Dengue or Yellow Fever Vaccine Completed NCT00730288 Phase 2
22 Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1-, 2-, or 3- Dose Schedules (STAGE I) Followed by a Single Booster Injection of the Same Vaccine (STAGE II) 1 or 2 Years After the Last Primary Dose in Healthy Subjects 9 to 50 Years of Age in Colombia and the Philippines Completed NCT02628444 Phase 2
23 Phase II, Randomized, Double-blind, Placebo-controlled Study of Two Doses of WRAIR Live Attenuated Tetravalent Dengue Vaccine Formulations, Administered Six Months Apart, to Healthy Adults and Children Completed NCT00468858 Phase 2
24 Immunogenicity and Safety of Three Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
25 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Singapore Completed NCT02824198 Phase 2
26 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Completed NCT00993447 Phase 2
27 Exploration of Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity Following Various Administration Schedules With CYD Tetravalent Dengue Vaccine Completed NCT01943825 Phase 2
28 Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Completed NCT01064141 Phase 2
29 Immunogenicity and Large-Scale Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Singapore Completed NCT00880893 Phase 2
30 Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Viet Nam Completed NCT00875524 Phase 2
31 A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Comparison of Recombinant Factor VIIa (NovoSeven®) and Standard Haemostatic Replacement Therapy in Patients With Dengue Haemorrhagic Fever Completed NCT01601613 Phase 2 activated recombinant human factor VII;placebo
32 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Aged 18 to 50 Years in Brazil Active, not recruiting NCT02741128 Phase 2
33 Evaluation of the Safety and Immunogenicity of Heterologous Dengue Vaccine Administration in Dengue Immune Individuals Completed NCT00458120 Phase 1
34 Phase I Evaluation of the Safety and Immunogenicity of rDEN4delta30 Lot# 109A, a Live Attenuated DEN4 Vaccine, in Healthy Flavivirus-naïve Adult Volunteers. Completed NCT00919178 Phase 1
35 Effect of Baseline Dengue Serostatus Among Tetravalent Dengue Vaccine CYDTDV (Dengvaxia®) Recipients on Subsequent Virologically Confirmed Dengue in the Philippines Unknown status NCT03465254
36 Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children in India Completed NCT01477671
37 Prospective Study for the Evaluation of Dengue Prognostic Biomarkers in Singapore Completed NCT04048837
38 Long-Term Follow-Up of Hospitalized Dengue and Safety in Thai Children Who Were Included in an Efficacy Study of a Tetravalent Dengue Vaccine Completed NCT01983553
39 Association of Host Genetics With Vaccine Efficacy, and Evaluation of Immune Correlates of Risk From the First Proof of Concept Efficacy Study With a Tetravalent Dengue Vaccine Completed NCT02827162
40 Laboratory Diagnosis and Prognosis of Severe Dengue Completed NCT01421732
41 NT-proBNP and Troponin I in Children With Dengue Hemorrhagic Shock: a Longitudinal Study Recruiting NCT04837430
42 Effectiveness of the Tetravalent Dengue Vaccine, CYD-TDV (Dengvaxia®) in the Philippines Recruiting NCT03803618
43 Post-Authorization Safety Study: Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine Active, not recruiting NCT02948933

Search NIH Clinical Center for Dengue Hemorrhagic Fever

Cochrane evidence based reviews: severe dengue

Genetic Tests for Dengue Hemorrhagic Fever

Anatomical Context for Dengue Hemorrhagic Fever

Organs/tissues related to Dengue Hemorrhagic Fever:

MalaCards : Skin, Myeloid, Endothelial, T Cells, Liver, Monocytes, Thyroid

Publications for Dengue Hemorrhagic Fever

Articles related to Dengue Hemorrhagic Fever:

(show top 50) (show all 4030)
# Title Authors PMID Year
1
Super induction of dengue virus NS1 protein in E. coli. 53 62
19232392 2009
2
TNF and LTA gene, allele, and extended HLA haplotype associations with severe dengue virus infection in ethnic Thais. 53 62
19392621 2009
3
Recombinant non-structural 1 (NS1) protein of dengue-2 virus interacts with human STAT3beta protein. 53 62
15878791 2005
4
High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. 53 62
12355369 2002
5
Kinetics of dengue virus-specific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection. 53 62
11724841 2001
6
Association of self-reported allergic rhinitis with dengue severity: A case-control study. 62
36063904 2022
7
Generation and characterization of genetically and antigenically diverse infectious clones of dengue virus serotypes 1-4. 62
34931940 2022
8
Clinical and Laboratory Profile of Dengue in Kashmir Valley. 62
35057590 2022
9
Electrochemical detection of Zika and Dengue infections using a single chip. 62
36007411 2022
10
A human monoclonal antibody to neutralize all four serotypes of dengue virus derived from patients at the convalescent phase of infection. 62
36183498 2022
11
Atorvastatin attenuates NS1 (Non-structural protein-1) of dengue type-2 serotype-induced expressions of matrix metalloproteinases in HL-60 cells, differentiated to neutrophils: Implications for the immunopathogenesis of dengue viral disease. 62
36108401 2022
12
Sulforaphane suppresses dengue virus replication by inhibition of dengue protease and enhancement of antiviral interferon response through Nrf2-mediated heme oxygenase-1 induction. 62
36055433 2022
13
Recent advances in natural products as potential inhibitors of dengue virus with a special emphasis on NS2b/NS3 protease. 62
35948138 2022
14
TLR2 axis on peripheral blood mononuclear cells regulates inflammatory responses to non-infectious immature dengue virus particles. 62
36240261 2022
15
Molecular Determinants of Tissue Specificity of Flavivirus Nonstructural Protein 1 Interaction with Endothelial Cells. 62
36106873 2022
16
Clinical and hematological profiles of children with dengue residing in a non-endemic zone of Bangladesh. 62
36215330 2022
17
Antrodia cinnamomea Suppress Dengue Virus Infection through Enhancing the Secretion of Interferon-Alpha. 62
36235496 2022
18
Mimicking platelet indices in patients with malaria and dengue hemorrhagic fever: characteristics and clinical applications. 62
36221147 2022
19
Effect of prior Zika and dengue virus exposure on the severity of a subsequent dengue infection in adults. 62
36241869 2022
20
Early diagnostic markers in predicting the severity of dengue disease. 62
36091089 2022
21
Clinical and prognostic relevance of sST2 in adults with dengue-associated cardiac impairment and severe dengue. 62
36228040 2022
22
Hyperinflammatory Syndrome, Natural Killer Cell Function, and Genetic Polymorphisms in the Pathogenesis of Severe Dengue. 62
35267010 2022
23
Dengue algorithms integrated into the IMCI guidelines: An updated assessment in five Southeast-Asian countries. 62
36219610 2022
24
The utility of inflammatory and endothelial factors in the prognosis of severe dengue. 62
36257203 2022
25
Discovery and validation of circulating miRNAs for the clinical prognosis of severe dengue. 62
36251659 2022
26
CRISPR Cas9 mediated knockout of sex determination pathway genes in Aedes aegypti. 62
36259148 2022
27
A modified Sequential Organ Failure Assessment score for dengue: development, evaluation and proposal for use in clinical trials. 62
36057771 2022
28
Epidemiology (2012-2019) and costs (2009-2019) of dengue in Malaysia: a systematic literature review. 62
36089149 2022
29
Clinicopathological alteration of symptoms with serotype among dengue infected pediatric patients. 62
35578548 2022
30
COVID-19 Antibodies as Predictor of Severe Dengue among Hospitalized Children with Dengue Illness in the Post-third-wave Period of COVID-19 Infection in India. 62
36082886 2022
31
Clinical Profile, Severity Spectrum, and Hospital Outcome of Dengue Patients in a Tertiary Care Hospital in Dhaka City. 62
36225509 2022
32
Association of Neutrophil Mediators With Dengue Disease Severity and Cardiac Impairment in Adults. 62
36208158 2022
33
Establishment of SMS Dengue Severity Score. 62
36082881 2022
34
Elevated serum PAR-1 levels as an emerging biomarker of inflammation to predict the dengue infection severity. 62
36109338 2022
35
Prolonged fever and pancytopenia in a case of severe dengue may be secondary hemophagocytic lymphohistiocytosis. 62
36147439 2022
36
Acute acalculous cholecystitis in a pediatric dengue hemorrhagic fever patient: A case report, lesson learned from limited resource setting. 62
36147073 2022
37
A fatal case of dengue hemorrhagic fever associated with dengue virus 4 (DENV-4) in Brazil: genomic and histopathological findings. 62
35779208 2022
38
Efficacy of Dengue Vaccines in the Prevention of Severe Dengue in Children: A Systematic Review. 62
36225478 2022
39
Generation of soluble, cleaved, well-ordered, native-like dimers of dengue virus 4 envelope protein ectodomain (sE) suitable for vaccine immunogen design. 62
35817240 2022
40
Hyperglycemia exacerbates dengue virus infection by facilitating poly(A)-binding protein-mediated viral translation. 62
36125898 2022
41
Association of dengue virus non-structural-1 protein with disease severity: a brief review. 62
36125197 2022
42
Alpha-mangostin inhibits viral replication and suppresses nuclear factor kappa B (NF-κB)-mediated inflammation in dengue virus infection. 62
36168031 2022
43
Development and Characterization of a Genetically Stable Infectious Clone for a Genotype I Isolate of Dengue Virus Serotype 1. 62
36146879 2022
44
Suppression of TGF-β/Smad2 signaling by GW788388 enhances DENV-2 clearance in macrophages. 62
35596058 2022
45
Concurrent Typhoid Fever and Dengue Hemorrhagic Fever: A Case Report. 62
36185892 2022
46
Functional Loop Dynamics and Characterization of the Inactive State of the NS2B-NS3 Dengue Protease due to Allosteric Inhibitor Binding. 62
35950997 2022
47
Dengue Shock Syndrome: Its Similarity with Anaphylaxis and with the Homeopathic Medicine Apis mellifica (European Honeybee). 62
34749419 2022
48
Dengue Shock Syndrome, Anaphylaxis, and Homeopathic Medicine. 62
35253139 2022
49
Optimal Validated Multi-Factorial Climate Change Risk Assessment for Adaptation Planning and Evaluation of Infectious Disease: A Case Study of Dengue Hemorrhagic Fever in Indonesia. 62
36006264 2022
50
Serum soluble interleukin-2 receptor (sIL-2R) is an accurate biomarker for dengue-associated hemophagocytic lymphohistiocytosis syndrome diagnosed by Hscore. 62
35999341 2022

Variations for Dengue Hemorrhagic Fever

Expression for Dengue Hemorrhagic Fever

LifeMap Discovery
Genes differentially expressed in tissues of Dengue Hemorrhagic Fever patients vs. healthy controls: 35 (show top 50) (show all 120)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CD38 CD38 molecule Blood + 4.80 0.000
2 IFI27 interferon alpha inducible protein 27 Blood + 4.71 0.000
3 RRM2 ribonucleotide reductase regulatory subunit M2 Blood + 4.63 0.000
4 IGHM immunoglobulin heavy constant mu Blood + 4.61 0.000
5 BIRC5 baculoviral IAP repeat containing 5 Blood + 4.47 0.000
6 CAV1 caveolin 1 Blood + 4.41 0.000
7 DLGAP5 DLG associated protein 5 Blood + 4.31 0.000
8 XIST X inactive specific transcript Blood - 4.31 0.023
9 CEP55 centrosomal protein 55 Blood + 4.28 0.000
10 BUB1 BUB1 mitotic checkpoint serine/threonine kinase Blood + 4.21 0.000
11 SHCBP1 SHC binding and spindle associated 1 Blood + 4.13 0.000
12 PBK PDZ binding kinase Blood + 4.13 0.000
13 IGKV3-20 immunoglobulin kappa variable 3-20 Blood + 4.13 0.000
14 TYMS thymidylate synthetase Blood + 4.07 0.000
15 CDCA2 cell division cycle associated 2 Blood + 4.06 0.000
16 MKI67 marker of proliferation Ki-67 Blood + 4.00 0.000
17 CYAT1 immunoglobulin lambda light chain-like Blood + 3.98 0.000
18 MCM10 minichromosome maintenance 10 replication initiation factor Blood + 3.98 0.000
19 CCN3 cellular communication network factor 3 Blood - 3.97 0.000
20 ZWINT ZW10 interacting kinetochore protein Blood + 3.96 0.000
21 CDK1 cyclin dependent kinase 1 Blood + 3.92 0.000
22 HMMR hyaluronan mediated motility receptor Blood + 3.90 0.000
23 SDC1 syndecan 1 Blood + 3.89 0.000
24 SPC25 SPC25 component of NDC80 kinetochore complex Blood + 3.84 0.000
25 NCAPG non-SMC condensin I complex subunit G Blood + 3.84 0.000
26 TK1 thymidine kinase 1 Blood + 3.82 0.000
27 CDC20 cell division cycle 20 Blood + 3.80 0.000
28 TNFRSF17 TNF receptor superfamily member 17 Blood + 3.80 0.000
29 DTL denticleless E3 ubiquitin protein ligase homolog Blood + 3.80 0.000
30 TOP2A DNA topoisomerase II alpha Blood + 3.80 0.000
31 PI3 peptidase inhibitor 3 Blood - 3.76 0.000
32 GLDC glycine decarboxylase Blood + 3.75 0.000
33 IGLJ3 immunoglobulin lambda joining 3 Blood + 3.75 0.000
34 SESN3 sestrin 3 Blood - 3.75 0.000
35 KIF2C kinesin family member 2C Blood + 3.74 0.000
36 CDT1 chromatin licensing and DNA replication factor 1 Blood + 3.72 0.000
37 CDKN3 cyclin dependent kinase inhibitor 3 Blood + 3.71 0.000
38 PCLAF PCNA clamp associated factor Blood + 3.71 0.000
39 EIF1AY eukaryotic translation initiation factor 1A Y-linked Blood + 3.71 0.034
40 CNTNAP3 contactin associated protein family member 3 Blood - 3.70 0.000
41 CENPA centromere protein A Blood + 3.69 0.000
42 TTK TTK protein kinase Blood + 3.67 0.000
43 ASPM assembly factor for spindle microtubules Blood + 3.66 0.000
44 KIF11 kinesin family member 11 Blood + 3.64 0.000
45 IGL immunoglobulin lambda locus Blood + 3.64 0.000
46 CCNB2 cyclin B2 Blood + 3.61 0.000
47 BUB1B BUB1 mitotic checkpoint serine/threonine kinase B Blood + 3.60 0.000
48 CDC6 cell division cycle 6 Blood + 3.60 0.000
49 SLC2A5 solute carrier family 2 member 5 Blood + 3.60 0.000
50 DUSP5 dual specificity phosphatase 5 Blood + 3.60 0.000
Search GEO for disease gene expression data for Dengue Hemorrhagic Fever.

Pathways for Dengue Hemorrhagic Fever

Pathways related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.68 CCR6 CD209 CD4 CD40LG CD8A CLEC5A
2
Show member pathways
13.63 CCR6 CD4 CD40LG CXCL8 IFNA1 IL10
3
Show member pathways
13.54 CD4 CXCL8 IFNA1 IL10 IL6 LTA
4
Show member pathways
13.4 TNF LTA IL6 IL10 CXCL8 CD40LG
5
Show member pathways
13.26 CCR6 CD4 CD40LG CXCL8 IL10 IL6
6
Show member pathways
13.18 TNF PTPN11 LTA IL6 IL10 IFNA1
7
Show member pathways
12.83 TNF IL6 IFNA1 CXCL8 CLEC4M CD209
8
Show member pathways
12.63 TNF PTPN11 IL6 CXCL8 CD209
9
Show member pathways
12.59 TNF PTPN11 IL6 IL10 CD4
10 12.57 TNF IL10 IFNA1 CD8A CD40LG
11
Show member pathways
12.54 CXCL8 HLA-B IFNA1 IL10 IL6 LTA
12
Show member pathways
12.51 TNF IL6 IFNA1 CXCL8
13
Show member pathways
12.31 TNF PTPN11 IL6 CXCL8
14 12.18 TNF IL6 IL10 CXCL8
15 12.11 TNF LTA IL6 IL10
16
Show member pathways
12.03 TNF LTA IL10 CD8A CD40LG CD4
17 11.98 TNF IL6 FCGR2A CXCL8
18 11.95 TNF IL6 IL10 CXCL8
19
Show member pathways
11.92 TNF LTA IL6 IL10 CD4
20 11.89 CCR6 CXCL8 IL10 IL6
21 11.86 TNF IL10 HLA-B CXCL8 CD40LG
22
Show member pathways
11.79 TNF LTA FCGR2A
23
Show member pathways
11.79 IL6 CXCL8 CD8A CD4
24 11.77 IL6 FCGR2A CXCL8
25 11.77 IL6 IL10 CD40LG CD4
26 11.75 TNF IL6 CXCL8
27 11.74 TNF IL6 IL10 CD40LG
28 11.72 IL6 IL10 CXCL8
29
Show member pathways
11.7 TNF CXCL8 CD40LG
30
Show member pathways
11.68 TNF IL6 CXCL8 CD40LG
31 11.67 TNF IL6 CXCL8
32 11.66 TNF IL6 IL10 CXCL8
33 11.64 LTA IL10 CD40LG
34
Show member pathways
11.63 TNF IL6 IL10
35 11.6 PTPN11 IL6 CXCL8
36 11.57 TNF PTPN11 IL10
37 11.57 TNF IL6 CXCL8 CD40LG
38 11.56 TNF IL10 CXCL8
39 11.55 TNF IL10 CD40LG CD4
40 11.54 TNF LTA IL10 CD8A CD4 CCR6
41 11.52 TNF IL6 IL10 CXCL8
42 11.51 TNF LTA IL6 IL10 CD40LG
43 11.4 IL10 FCGR2A CD4
44 11.37 IL10 IL6 TNF
45 11.3 TNF IL6 IL10 CD8A CD4 CD209
46 11.29 TNF IL6 CXCL8
47 11.24 TNF IL6 IL10 CD4
48 11.23 TNF IL6 IL10 FCGR2A CD8A CD4
49 11.2 TNF IL6 IFNA1 CXCL8
50 11.06 TNF IL6 CXCL8

GO Terms for Dengue Hemorrhagic Fever

Cellular components related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.97 TNF HLA-B CLEC5A CD40LG CD4 CD209
2 external side of plasma membrane GO:0009897 9.8 TNF CLEC4M CD8A CD40LG CD4 CD209
3 plasma membrane GO:0005886 9.75 CCR6 CD4 CD40LG CD8A CLEC4M CLEC5A
4 plasma membrane GO:0005887 9.75 CCR6 CD4 CD40LG CD8A CLEC4M CLEC5A

Biological processes related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.49 CCR6 CD4 CD40LG CLEC5A CXCL8 IL10
2 adaptive immune response GO:0002250 10.35 IFNA1 HLA-B CLEC4M CD8A CD4 CD209
3 viral entry into host cell GO:0046718 10.13 CD209 CD4 CLEC4M CLEC5A
4 B cell proliferation GO:0042100 10.09 IL10 IFNA1 CD40LG
5 response to activity GO:0014823 10.09 TNF IL6 IL10
6 calcium-mediated signaling GO:0019722 10.06 TNF CXCL8 CD4 CCR6
7 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.02 TNF IL6 IL10
8 leukocyte cell-cell adhesion GO:0007159 10.01 CLEC4M CD40LG CD209
9 liver regeneration GO:0097421 9.99 TNF IL6 IL10
10 defense response GO:0006952 9.96 TNF IFNA1 HLA-B CXCL8
11 cell-cell recognition GO:0009988 9.91 CLEC4M CD209
12 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.9 TNF LTA
13 negative regulation of cytokine production involved in immune response GO:0002719 9.89 TNF IL10
14 virion attachment to host cell GO:0019062 9.87 CD209 CLEC4M
15 immune system process GO:0002376 9.86 HLA-B FCGR2A CLEC5A CLEC4M CD8A CD4
16 intracellular transport of virus GO:0075733 9.8 CLEC4M CD209
17 positive regulation of glial cell proliferation GO:0060252 9.8 IL6 LTA TNF
18 peptide antigen transport GO:0046968 9.78 CLEC4M CD209
19 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.71 TNF LTA
20 antigen processing and presentation GO:0019882 9.7 HLA-B CLEC4M CD8A CD209
21 chronic inflammatory response to antigenic stimulus GO:0002439 9.67 TNF IL10
22 humoral immune response GO:0006959 9.65 CCR6 IFNA1 IL6 LTA TNF
23 signaling GO:0023052 9.61 TNF LTA CD40LG
24 immune response GO:0006955 9.47 TNF LTA IL6 IL10 HLA-B CXCL8

Molecular functions related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 9.73 HLA-B CLEC4M CD209
2 tumor necrosis factor receptor binding GO:0005164 9.63 TNF LTA CD40LG
3 virus receptor activity GO:0001618 9.56 CLEC5A CLEC4M CD4 CD209
4 cytokine activity GO:0005125 9.44 TNF LTA IL6 IL10 IFNA1 CXCL8

Sources for Dengue Hemorrhagic Fever

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....